Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer…
PHOENIX, July 16, 2024 /PRNewswire/ -- Trinity Capital Inc. ("Trinity") (NASDAQ: TRIN, TRINL, TRINZ), an internally managed business development company,…